DeepMed Research

ETOP IBCSG Partners Foundation

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Stage III

Interventions: Drug: Nivolumab

First Posted Date: 2015-05-05

Last Posted Date: 2022-08-24

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 94

Registration Number: NCT02434081

Locations: 🇨🇭
HFR Fribourg- Hôpital cantonal, Fribourg, Switzerland
🇳🇱
VUMC, Amsterdam, Netherlands
🇨🇭
Kantonsspital Winterthur, Winterthur, Switzerland

and more 8 locations

IBCSG Trial 22-00 Serum Substudy

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Procedure: Blood samples collection

First Posted Date: 2015-03-19

Last Posted Date: 2021-05-18

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 136

Registration Number: NCT02393833

Locations: 🇮🇹
Istituto Europeo di Oncologia (IEO, Milano, Italy

Afatinib in NSCLC With HER2 Mutation

Phase 2

Completed

Conditions: NSCLC

Interventions: Drug: Afatinib

First Posted Date: 2015-02-24

Last Posted Date: 2022-08-24

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 13

Registration Number: NCT02369484

Locations: 🇨🇭
CHUV, Lausanne, Switzerland
🇨🇭
USZ, Zürich, Switzerland
🇳🇱
NKI-AVL, Amsterdam, Netherlands

and more 2 locations

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

Not Applicable

Active, not recruiting

Conditions: Early Breast Cancer

Interventions: Other: Endocrine therapy interruption

First Posted Date: 2014-12-04

Last Posted Date: 2024-04-23

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 518

Registration Number: NCT02308085

Locations: 🇺🇸
Mattoon Charleston Primary Care, Mattoon, Illinois, United States
🇺🇸
Sanford Bismark Medical Centre, Bismarck, North Dakota, United States
🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada

and more 205 locations

Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy

Phase 3

Terminated

Conditions: Lung Cancer Non-small Cell Stage IV

Interventions: Other: None, standard chemotherapy only
Drug: Denosumab

First Posted Date: 2014-05-02

Last Posted Date: 2024-04-25

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 595

Registration Number: NCT02129699

Locations: 🇦🇹
Univ. Klinik für Innere Medizin V, Innsbruck, Austria
🇦🇹
KH der Elisabethinen Linz, Linz, Austria
🇦🇹
AKH Wien, Wien, Austria

and more 63 locations

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: MK-3475

First Posted Date: 2014-05-02

Last Posted Date: 2019-02-15

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 58

Registration Number: NCT02129556

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria
🇧🇪
Jules Bordet Institute, Brussels, Belgium
🇧🇪
CHU Sart Tilman, Liège, Belgium

and more 8 locations

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

Phase 2

Completed

Conditions: Limited Stage Small Cell Lung Cancer
Small Cell Lung Cancer

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2014-01-28

Last Posted Date: 2024-11-08

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 222

Registration Number: NCT02046733

Locations: 🇦🇺
Royal Hobart Hospital, Hobart, Australia
🇪🇸
Hospital Universitario 12 Octubre, Madrid, Spain
🇦🇺
Coffs Harbour Health Campus, Coffs Harbour, Australia

and more 54 locations

TRial on the Endocrine Activity of Neoadjuvant Degarelix

Phase 2

Completed

Conditions: Breast Cancer Invasive Nos

Interventions: Drug: triptorelin
Drug: degarelix
Drug: letrozole

First Posted Date: 2013-12-09

Last Posted Date: 2019-05-29

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 51

Registration Number: NCT02005887

Locations: 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna, Bologna, Italy
🇮🇹
Istituto Toscana Tumori, Prato, Italy
🇮🇹
Ospedale degli Infermi, Rimini, Italy

and more 4 locations

Schedules of Nab-Paclitaxel in Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breastcancer

Interventions: Drug: nab-Paclitaxel

First Posted Date: 2012-12-10

Last Posted Date: 2023-06-01

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 258

Registration Number: NCT01746225

Locations: 🇧🇪
CHR de la Citadelle, Oncology-Haematology Unit, Liège, Belgium
🇧🇪
CHU Sart Tilman, Medical Oncology, Liège, Belgium
🇮🇪
Mid-Western Regional Hospital, Limerick, Ireland

and more 38 locations

Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Erlotinib
Drug: Docetaxel

First Posted Date: 2012-07-30

Last Posted Date: 2022-08-24

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 81

Registration Number: NCT01652469

Locations: 🇦🇹
Krankenhaus Hietzing, Wien, Austria
🇭🇺
National Institute of Oncology, Budapest, Hungary
🇮🇪
St James's Hospital, Dublin, Ireland

and more 29 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy